Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs.

Ruoxi Hong; Fei MA; Xiuqing Shi; Qing LI; Pin Zhang; Peng Yuan; Jiayu Wang; Ying Fan; Ruigang Cai; Qiao LI; Binghe XU

Return

Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs.

Author: Ruoxi HONG ¹ ; Fei MA ¹ ; Xiuqing SHI ¹ ; Qing LI ¹ ; Pin ZHANG ¹ ; Peng YUAN ¹ ; Jiayu WANG ¹ ; Ying FAN ¹ ; Ruigang CAI ¹ ; Qiao LI ¹ ; Binghe XU ²
Author Information

1. Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Email: xubinghe@medmail.com.cn.
Publication Type:Clinical Trial
MeSH: Antineoplastic Agents; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Disease-Free Survival; Humans; Lung Neoplasms; drug therapy; Neoplasms, Second Primary; Platinum; therapeutic use; Triple Negative Breast Neoplasms; drug therapy
From: Chinese Journal of Oncology 2014;36(10):788-792
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo compare the effect of first-line treatment with platinum-based chemotherapy and non-platinum-based chemotherapy in patients with lung metastases from triple negative breast cancer (TNBC).
METHODSSixty-five eligible patients were divided into platinum-treated group and non-platinum-treated group according to the first-line therapy. Factors predicting the chemotherapeutic efficacy included overall survival (OS), progression-free survival (PFS) and objective response (OR).
RESULTSIn the platinum-treated group of 32 patients, 2 cases (6.3%) achieved CR, 16 cases (50.0%) achieved PR, 11 (34.4%) cases achieved SD, and 3 patients (9.4%) achieved PD. In the non-platinum-treated group of 33 patients, 2 cases (6.1%) achieved CR, 6 cases (18.2%) achieved PR, 16 cases (48.5%) achieved SD, and 9 cases (27.3%) achieved PD. Median PFS was significantly longer in the platinum-treated group than in the non-platinum-treated group (10 months vs. 6.0 months, P = 0.012), and OS was also improved (32 months vs. 22 months, P = 0.006). Multivariate analysis of several factors including local-regional lymph node involvement, lung metastasis-related symptoms, first-line platinum-based chemotherapy, disease-free interval, size and number of lung lesions, showed that first-line platinum-based chemotherapy was an independent prognostic factor for TNBC patients with lung metastases.
CONCLUSIONSCompared with non-platinum-based chemotherapy, the first-line platinum-based chemotherapy can improve PFS and OS in TNBC patients with metastases confined to the lungs.